RXRX Stock — Recursion Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$3.83

Market cap

$2,050.4M

Cash

$545.7M

Enterprise value

$1,504.7M

Balance sheet

Cash	$545.7M
Debt	$0.0M
Net cash	$545.7M
Enterprise value	$1,504.7M
Basic shares	534.1M shares
Fully diluted shares	561.0M shares
Fully diluted market cap	$2,148.8M
Cash per share	$1.02

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading RXRX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jul 13 - Aug 24	REC-4881	Phase 2	Familial Adenomatous Polyposis	—
Feb 12 - Mar 25	GTAEXS617	Phase 2	Head and Neck Squamous Cell Carcinoma (HNSCC); Pancreatic Adenocarcinoma; Non-small Cell Lung Cancer (NSCLC)	—
Jul 13 - Aug 24	EXS73565	Phase 1	Relapsed or Refractory B-cell Malignancies; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL); Follicular Lymphoma (FL)	—
Dec 11, 2028 - Jan 22, 2029	REC-1245	Phase 2	Unresectable; Locally Advanced; Metastatic Cancers	—
Apr 12 - May 24	EXS74539	Phase 1	Solid Tumor; Small Cell Lung Cancer (SCLC); High Grade Neuroendocrine Cancer	—
Feb 12 - Mar 26	REC-7735	Phase 2	Solid Tumors	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

REC-4881

Phase 2 · Active Modality: small molecule

Target MEK1/2

Indications

Familial adenomatous polyposis (FAP) (Phase 2)

Catalysts

— 2H26
— November 2026

Status note TUPELO Phase 1b/2 study enrolling patients ages 18 and older plus a cohort with an alternative dosing schedule. Orphan Drug Designation granted in the US and EU.

REC-1245

Phase 1 · Active

Target RBM39

Indications

Unresectable (Phase 2)
Locally Advanced (Phase 2)
Metastatic Cancers (Phase 2)

Catalysts

— 2H26

Status note Phase 1 dose escalation ongoing.

REC-617

Phase 1 · Active

Target CDK7

Indications

not disclosed (Phase 1)

Catalysts

— 1H27

Status note Phase 1 combination study ongoing.

REC-3565

Phase 1 · Active

Target MALT1

Indications

not disclosed (Phase 1)

Catalysts

— 1H27

Status note Phase 1 monotherapy study ongoing.

REC-4539

Phase 1 · Active

Target LSD1

Indications

not disclosed (Phase 1)

Catalysts

— 2H27

Status note Phase 1 monotherapy study ongoing.

REC-7735

Preclinical · Active

Target PI3Kα H1047R

Indications

Select PIK3CA H1047R-mutant solid tumors (Preclinical)

Catalysts

— 2H26

Status note IND cleared; Phase 1/2 ZINNIA study to be initiated in the second half of 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	REC-4881
Lead indication	Familial Adenomatous Polyposis
Lead phase	Phase 2
Active trials	6

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05552755	Phase 2	Recruiting	Sponsor	RXRX	—	Familial Adenomatous Polyposis	—
NCT05985655	Phase 2	Recruiting	Sponsor	RXRX	—	Head and Neck Squamous Cell Carcinoma (HNSCC); Pancreatic Adenocarcinoma; Non-small Cell Lung Cancer (NSCLC)	—
NCT06678659	Phase 2	Recruiting	Sponsor	RXRX	—	Unresectable; Locally Advanced; Metastatic Cancers	—
NCT07819136	Phase 2	Not yet recruiting	Sponsor	RXRX	—	Solid Tumors	—
NCT06980116	Phase 1	Recruiting	Sponsor	RXRX	—	Relapsed or Refractory B-cell Malignancies; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL); Follicular Lymphoma (FL)	—
NCT07517198	Phase 1	Recruiting	Sponsor	RXRX	—	Solid Tumor; Small Cell Lung Cancer (SCLC); High Grade Neuroendocrine Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (6 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 6 active trials for Recursion Pharmaceuticals Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	41,000	+6,000	0.01%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

RXRX — Recursion Pharmaceuticals Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders